Bayer AG

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Bayer AG engages in the business of life science fields of healthcare and nutrition. It operates through the following segments: Crop Science, Pharmaceuticals, and Consumer Health. The Crop Science segment includes developing, producing, and marketing products in seeds and plant traits, crop protection, digital solutions, and customer services to promote sustainable agriculture. The Pharmaceuticals segment is involved in prescription products especially for cardiology and women’s health; specialty therapeutics in the areas of oncology, hematology, ophthalmology, and cell and gene therapy; diagnostic imaging equipment; and necessary contrast agents. The Consumer Health segment focuses on non-prescription products in the dermatology, nutritional supplements, digestive health, allergy, cough and cold, and pain and cardiovascular risk prevention categories. The company was founded by Friedrich Bayer and Johann Friedrich Westkott on August 1, 1863 and is headquartered in Leverkusen, Germany.

Bayer, following the Monsanto M&A, has become one of the largest agrochemical company in the world. I wouldn't touch the company at normal valuation currently, following the liability risks.

Bayer: Consider The Company At Dirt-Cheap Valuation

The $4 billion deal will give the company's presence in the gene therapy space a huge boost.

Bayer to Acquire a Lead Position in America's Gene Therapy Space

German pharma and life sciences company Bayer AG (OTC: BAYRY) has acquired U.S.-based gene therapy biotech company Asklepios Biopharmaceutical Inc (AskBio) in a deal valued up to $4 billion. The purchase price of $2 billion will be paid upfront, and the remaining half will be payable in success-based milestone payments.

Bayer Acquires AskBio For $4 Billion To Strengthen Its Gene Therapy Platform

Bayer agreed to acquire unlisted U.S. biotech firm Asklepios BioPharmaceutical Inc for as much as $4 billion in a bet on gene therapy with the help of modified viruses.

Bayer to acquire Asklepios Bio in foray into gene therapy worth up to $4 billion

BERLIN--(BUSINESS WIRE)--Bayer AG today announced the acquisition of Asklepios BioPharmaceutical, Inc. (AskBio), a US-headquartered biopharmaceutical company specialized in the research, development and manufacturing of gene therapies across different therapeutic areas. AskBio's development portfolio includes investigational pre-clinical and clinical stage candidates for the treatment of neuromuscular, central nervous system, cardiovascular and metabolic diseases. Bayer will own full rights to

Bayer Acquires Asklepios BioPharmaceutical to Broaden Innovation Base in Cell and Gene Therapy

WHIPPANY, N.J.--(BUSINESS WIRE)--Bayer announced today that detailed results from the FIDELIO-DKD Phase III study demonstrated that the investigational drug finerenone slowed the progression of chronic kidney disease (CKD) in patients with CKD and type 2 diabetes (T2D) compared to placebo. In the study, finerenone significantly reduced the risk of the composite primary endpoint of time to kidney failure, a sustained decrease of estimated glomerular filtration rate (eGFR) greater than or equal t

Bayer's FIDELIO-DKD Phase III Study Demonstrated Investigational Drug Finerenone Significantly Reduced Renal and Cardiovascular Outcomes in Patients with Chronic Kidney Disease and Type 2 Diabetes

Bayer's Monsanto division on Wednesday lost a final appeal in a long-running French legal battle in which the crop chemical maker has been held liable for the accidental inhalation of a weedkiller by a crop farmer.

Monsanto loses final appeal over French farmer's weedkiller accident

Bayer's (BAYRY) Aliqopa combined with Rituxan met the primary endpoint of significantly prolonging PFS in a phase III study in patients with relapsed indolent non-Hodgkin's lymphoma.

Bayer's Aliqopa Meets Primary Endpoint in Lymphoma Study

Biogen

Bayer's recent weakness may not end anytime soon.

Better Buy: Biogen vs. Bayer

Bayer: 3 Ways To Value The Company

WHIPPANY, N.J.--(BUSINESS WIRE)--Bayer, a leader in women's healthcare, announced today the submission of a supplemental new drug application (sNDA) to the U.S. Food and Drug Administration (FDA) to potentially extend the duration of use for its market leading1 intrauterine device (IUD) Mirena® (levonorgestrel-releasing intrauterine system) 52 mg. In August, Mirena received approval from the FDA to extend its indication for up to six years of pregnancy prevention. This new submission will seek

Bayer Submits Supplemental New Drug Application to FDA for Intrauterine Device (IUD) Mirena® (levonorgestrel-releasing intrauterine system) 52 mg

Looking for value in the pharmaceuticals sector? These two stocks have you covered.

2 Top Pharma Stocks to Buy in October

WHIPPANY, N.J.--(BUSINESS WIRE)--Bayer will present detailed results from the Phase III FIDELIO-DKD study assessing the use of the investigational drug finerenone on kidney and cardiovascular outcomes in patients with chronic kidney disease (CKD) and type 2 diabetes (T2D) during scientific sessions of the upcoming American Society of Nephrology’s (ASN) Kidney Week, October 22-25, 2020. Additional data evaluating use of finerenone will also be presented. The FIDELIO-DKD study, which evaluated th

Bayer to Present Results From Phase III FIDELIO-DKD Study with Finerenone in Patients with Chronic Kidney Disease and Type 2 Diabetes during Late-Breaker Session at the American Society of Nephrology’s Kidney Week 2020

Bayer: Bear Vs. Bull

High debt levels, a damaged reputation, a potential ban of glyphosate and high settlement payments are putting Bayer in a tough position.

Bayer: I Finally Pulled The Trigger

GameStop

Stitch Fix

Here are three unconventional stocks that are significantly cheaper than they look.

3 Intriguing Value Stocks That Could Make You Rich

Bayer (BAYRY) confirmed its adjusted guidance for 2020 and expects 2021 sales approximately in line with 2020 levels, despite significant headwinds from the COVID-19 pandemic.

Bayer (BAYRY) Provides Bleak Guidance for 2021 Crop Division

Shares in Bayer plunged 11% after it flagged that adjusted profit may slip next year and it may have to write down the value of agriculture assets by close to 10 billion euros ($11.7 billion).

Bayer shares plunge on prospect of write-downs, earnings decline

ST. LOUIS--(BUSINESS WIRE)--Bayer announced today that the European Commission has authorized XtendFlex soybean technology for food, feed, import and processing in the European Union. This milestone represents the final key authorization for XtendFlex soybeans. With this approval in hand, Bayer can now look forward to a full launch in the United States and Canada in 2021 and expects to be in a strong position to supply 20 million U.S. soy acres when the selling season arrives. “XtendFlex soybea

Bayer’s XtendFlex Soybeans Gain Final Key Regulatory Approval

Bank of New York Mellon

Bristol-Myers

British American Tobacco

Cerner

GlaxoSmithKline

Imperial Brands PLC

Intel

Altria

Merck

Philip Morris

Roche Holding AG

Wide-Moat Stocks On Sale - The October 2020 Heat Map

Attorneys for Bayer AG and consumers suing the company over allegations its Roundup weedkiller caused cancer told a judge on Thursday they are continuing to resolve thousands more cases, improving prospects for its $11 billion deal to end the litigation.

Bayer resolves more Roundup cases, judge keeps pause on litigation

Chemicals giant Bayer and the U.S. government cooperated closely last year to lobby Thailand to reverse its ban on glyphosate, used in the company's controversial weedkiller Roundup, documents obtained by an environmental group and reviewed by Reuters show.

Exclusive: In the weeds - How Bayer, U.S. government teamed up against Thailand's glyphosate ban

Bayer AG has settled thousands of U.S. Roundup weed killer lawsuits as part of an $11 billion settlement, reaching deals with the only lawyers who took cases to trial over allegations the herbicide caused cancer.

Bayer settles thousands of U.S. Roundup cases with trial attorneys

WHIPPANY, N.J.--(BUSINESS WIRE)--Bayer has entered into an exclusive global license agreement with Systems Oncology, LLC, for ERSO™, a compound in pre-clinical development for metastatic Estrogen Receptor (ER) positive, breast cancer.

Bayer and Systems Oncology Sign Exclusive License Agreement for Investigational Breast Cancer Treatment Approach ERSO™

NEW YORK, Sept. 14, 2020 /PRNewswire/ --Pomerantz LLP is investigating claims on behalf of investors Bayer Aktiengesellschaft ("Bayer" or the "Company") (OTCMKTS: BAYRY).

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Bayer Aktiengesellschaft - BAYRY

News for Bayer AG Stock (BAYRY)